CARD17

Across TCGA pan-cancer cohorts, CARD17 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CARD17 data layer compared with 3 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CARD17 RNA is associated with better overall survival. In most high-consensus cancer types, elevated CARD17 expression acts as an unfavorable survival marker, although some lineages such as SKCM and ESCA show a favorable association.

SKCM, LGG, and THYM are the cancer types where CARD17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.443	0.254	<.001	64	view →
LGG	OS	Tertile	All	0.700	0.847	<.001	54	view →
THYM	DFS	Median	II,III,IV	0.742	0.941	.002	52	view →
LAML	DFS	Quartile	All	0.232	0.574	.002	30	view →
UVM	DFS	Tertile	II,III,IV	0.349	0.670	.011	21	view →
KIRC	DFS	Median	All	0.765	0.839	.011	21	view →
ESCA	DFS	Tertile	II,III,IV	0.831	0.120	.007	18	view →
SARC	OS	Quartile	All	0.848	0.669	.004	18	view →
STAD	DFS	Tertile	III,IV	0.421	0.677	.016	15	view →
GBM	OS	Tertile	All	0.275	0.571	<.001	14	view →
HNSC	OS	Tertile	IV	0.486	0.768	.006	14	view →
LIHC	DFS	Median	All	0.408	0.192	.001	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CARD17–SKCM (OS)

Open the SKCM breakdown →